[1] Mazmanian has described and defined a novel paradigm in science whereby the gut microbiome intricately controls the development and function of the mammalian immune system.
These discoveries include the demonstration that B. fragilis can treat experimental inflammatory bowel disease by inducing the activity of protective, regulatory immune cells.
Axial aimed to 'microbiota analysis to better understand the relationship between microbes and the central nervous system', and raised $102m with early investors including Longwood Fund.
[2][3][4][5] The New York Times noted Symbiotix as 'developing a complex sugar called PSA, which is associated with Bacteroides fragilis, into treatments for intestinal disease and multiple sclerosis'.
[7] He was awarded a Helen Hay Whitney Postdoctoral Fellowship at Harvard Medical School, before moving to Caltech in 2006, where he established the microbiome department.